Adalimumab-induced paradoxical pustular psoriasis and alopecia successfully treated with ixekizumab in a patient affected by hidradenitis suppurativa by Carlo Alberto Vignoli, Luigi Gargiulo, Federica Sanna, Alessandra Narcisi, Antonio Costanzo

Connect to this object online.

Intra-class switch among interleukin-17 inhibitors for the treatment of plaque psoriasis: a single-center experience by Gioele Ghezzi, Luciano Ibba, Luigi Gargiulo, Alessandra Narcisi, Antonio Costanzo, Mario Valenti

Connect to this object online.

A severe psoriasis flare after COVID-19 treated with risankizumab: complete skin clearance after 16 weeks by Luciano Ibba, Luigi Gargiulo, Giulia Pavia, Alessandra Narcisi, Antonio Costanzo, Mario Valenti

Connect to this object online.

Biologics for the Treatment of Severe Acrodermatitis Continua of Hallopeau: Report of Two Cases Successfully Treated with Ixekizumab and Ustekinumab by Luigi Gargiulo, Francesco Toso, Luciano Ibba, Mario Valenti, Antonio Costanzo, Alessandra Narcici

Connect to this object online.

Real-Life Safety and Effectiveness of Dupilumab in Patients With Concomitant Malignancies: A Case Series by Luigi Gargiulo, Carlo Alberto Vignoli, Andrea Cortese, Luciano Ibba, Antonio Costanzo, Alessandra Narcisi

Connect to this object online.

Risankizumab for the Treatment of Palmoplantar Pustular Psoriasis: A Report of Two Cases by Luigi Gargiulo, Carlo Alberto Vignoli, Giulia Pavia, Alessandra Narcisi, Antonio Costanzo, Chiara Perugini

Connect to this object online.

Upadacitinib for the treatment of atopic dermatitis in the elderly: an Italian case series of seven patients by Francesco Piscazzi, Luigi Gargiulo, Luciano Ibba, Mario Valenti, Paola Facheris, Antonio Costanzo, Alessandra Narcisi

Connect to this object online.

Upadacitinib for the treatment of concomitant psoriasis and atopic dermatitis: a case series by Luigi Gargiulo, Luciano Ibba, Giulia Pavia, Jessica Avagliano, Andrea Cortese, Antonio Costanzo, Alessandra Narcisi

Connect to this object online.

Tralokinumab rapidly improves subjective symptoms and quality of life in patients with moderate-to-severe atopic dermatitis: a real-life 16-week experience by Luigi Gargiulo, Luciano Ibba, Carlo Alberto Vignoli, Paola Facheris, Mario Valenti, Antonio Costanzo, Alessandra Narcisi

Connect to this object online.

Anti-IL-23 and anti-IL-17 drugs for the treatment of non-pustular palmoplantar psoriasis: a real-life retrospective study by Luciano Ibba, Luigi Gargiulo, Angela Alfano, Ruggero Cascio Ingurgio, Alessandra Narcisi, Antonio Costanzo, Mario Valenti

Connect to this object online.

Safety of anti-IL-23 drugs in patients with moderate-to-severe plaque psoriasis and previous tuberculosis infection: a monocentric retrospective study by Luciano Ibba, Luigi Gargiulo, Carlo Alberto Vignoli, Giovanni Fiorillo, Mario Valenti, Antonio Costanzo, Alessandra Narcisi

Connect to this object online.

Real-life effectiveness and safety of dupilumab in adolescents with atopic dermatitis: a 52-week single-center retrospective study by Luigi Gargiulo, Carlo Alberto Vignoli, Luciano Ibba, Andrea Cortese, Mario Valenti, Antonio Costanzo, Alessandra Narcisi

Connect to this object online.

Long-term management of pediatric psoriasis with ixekizumab: a case report by Diego Orsini, Luciano Ibba, Alessandra Narcisi, Pasquale Frascione, Alessia Pacifico, Mario Valenti, Antonio Costanzo, Luigi Gargiulo

Connect to this object online.

Apremilast for the treatment of pustular psoriasis induced by neoadjuvant ifosfamide + etoposide chemotherapy for Ewing Sarcoma: a case report by Mario Valenti, Luigi Gargiulo, Luciano Ibba, Alexia Bertuzzi, Sofia Manara, Francesco Toso, Antonio Costanzo, Alessandra Narcisi

Connect to this object online.

Dupilumab for the treatment of atopic dermatitis of the elderly: a real-life 52-week experience by Luigi Gargiulo, Francesco Piscazzi, Luciano Ibba, Mario Valenti, Paola Facheris, Chiara Perugini, Antonio Costanzo, Alessandra Narcisi

Connect to this object online.

Long-term effectiveness and safety of risankizumab in patients with moderate-to-severe psoriasis with and without cardiometabolic comorbidities: a single-center retrospective study by Luciano Ibba, Sara Di Giulio, Luigi Gargiulo, Paola Facheris, Chiara Perugini, Antonio Costanzo, Alessandra Narcisi, Mario Valenti

Connect to this object online.

Anti-IL17 and anti-IL23 biologic drugs for genital psoriasis: a single-center retrospective comparative study by Andrea Cortese, Luigi Gargiulo, Luciano Ibba, Giovanni Fiorillo, Francesco Toso, Carlo Alberto Vignoli, Alessandra Narcisi, Antonio Costanzo, Mario Valenti

Connect to this object online.

Effectiveness of risankizumab in plaque psoriasis with involvement of difficult-to-treat areas: a real-world experience from two referral centers by Diego Orsini, Luigi Gargiulo, Luciano Ibba, Ruggero Cascio Ingurgio, Mario Valenti, Chiara Perugini, Alessia Pacifico, Fabio S. Maramao, Pasquale Frascione, Antonio Costanzo, Alessandra Narcisi

Connect to this object online.

Upadacitinib 30 mg for the optimal management of moderate-to-severe atopic dermatitis: a 52-week single-center real-world study by Luigi Gargiulo, Luciano Ibba, Matteo Bianco, Sara Di Giulio, Alfano Alfano, Ruggero Cascio Ingurgio, Paola Facheris, Chiara Perugini, Mario Valenti, Antonio Costanzo, Alessandra Narcisi

Connect to this object online.

New-onset and flares of psoriasis after COVID-19 infection or vaccination successfully treated with biologics: a case series by Luigi Gargiulo, Luciano Ibba, Carlo A. Vignoli, Francesco Piscazzi, Andrea Cortese, Giovanni Fiorillo, Francesco Toso, Giulia Pavia, Mario Valenti, Jessica Avagliano, Alessandra Narcisi, Antonio Costanzo

Connect to this object online.